Open an account

Recursion Pharmaceuticals

RXRX · NASDAQ

$3.66+$0.05 (+1.39%)TodayMarket closed ·
Prev close $3.61

About RXRX

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah and currently employs 600 full-time employees. The company went IPO on 2021-04-16. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The firm integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

Employees
600
Headquarters
Salt Lake City, Utah
Listed
Apr 16, 2021
Sector
Health Care
Industry
Biotechnology
Website
recursion.com

RXRX key statistics

Market cap
2.19B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
33.15M
Volume
20.92M
Open price
$3.54
High today
$3.67
Low today
$3.47
52 Week high
$7.18
52 Week low
$2.77

Recursion Pharmaceuticals (RXRX) at a glance

As of Oct 20, 2026, Recursion Pharmaceuticals (RXRX) shares are priced at $3.66, giving the company a market cap of 2.19B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.47 and $3.67. The current price is 5.5% above the day's low and 0.3% below its high.

Volume so far is 20.92M shares, below the average of 33.15M shares a day.

Over the past year Recursion Pharmaceuticals has ranged from $2.77 to $7.18, and now sits 20% of the way up that range.

Recursion Pharmaceuticals met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.25 per share against an estimate of -$0.2387.

The average analyst price target is $6.79, 85.6% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

60%of 5 analyst ratings say Buy
  • Buy60.0%
  • Hold40.0%
  • Sell0.0%
Price target · 8 analystsAvg $6.79
Low
$4.04
Now
$3.66
High
$10.50

RXRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 14.3% on average.

  1. Q3 FY24: reported -$0.34 per share against an estimate of -$0.357
  2. Q4 FY24: reported -$0.53 per share against an estimate of -$0.4403
  3. Q1 FY25: reported -$0.50 per share against an estimate of -$0.5355
  4. Q2 FY25: reported -$0.41 per share against an estimate of -$0.357
  5. Q3 FY25: reported -$0.36 per share against an estimate of -$0.3774
  6. Q4 FY25: reported -$0.21 per share against an estimate of -$0.322
  7. Q1 FY26: reported -$0.22 per share against an estimate of -$0.2769
  8. Q2 FY26: reported -$0.25 per share against an estimate of -$0.2387

RXRX news

  • Mohd Haider

    Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know

  • Chandrima Sanyal

    Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up

  • Erica Kollmann

    Squeeze Watch: 10 Stocks With Over 33% Short Interest

  • Press releaseBusiness Wire

    Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model

  • Press releaseGlobe Newswire

    The Market Just Told You Which Layer Of AI Biology It Is Paying For

  • Mohd Haider

    Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why

  • Avi Kapoor

    Jim Cramer: These Utilities Stocks Are 'Oversold,' Fastly 'Back From The Abyss'

  • Press releasePRNewswire

    A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed

Similar companies

Companies in the same industry as Recursion Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.